-
1
-
-
0028115715
-
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate-or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study
-
Fisher, R.I.; Gaynor, E.R.; Dahlberg, S.; Oken, M.M.; Grogan, T.M.; et al. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate-or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann. Oncol. 1994, 5 (Suppl. 2), 91-95.
-
(1994)
Ann. Oncol.
, vol.5
, Issue.SUPPL. 2
, pp. 91-95
-
-
Fisher, R.I.1
Gaynor, E.R.2
Dahlberg, S.3
Oken, M.M.4
Grogan, T.M.5
-
2
-
-
0028790440
-
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
-
Philip, T.; Guglielmi, C.; Hagenbeek, A.; Somers, R.; Van der Lelie, H.; et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N. Engl. J. Med. 1995, 333 (23), 1540-1545.
-
(1995)
N. Engl. J. Med.
, vol.333
, Issue.23
, pp. 1540-1545
-
-
Philip, T.1
Guglielmi, C.2
Hagenbeek, A.3
Somers, R.4
Van Der Lelie, H.5
-
3
-
-
0029920432
-
The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: Identification of major prognostic groups
-
Prince, H.M.; Imrie, K.; Crump, M.; Stewart, A.K.; Girouard, C.; et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. Br. J. Haematol. 1996, 92 (4), 880-889.
-
(1996)
Br. J. Haematol.
, vol.92
, Issue.4
, pp. 880-889
-
-
Prince, H.M.1
Imrie, K.2
Crump, M.3
Stewart, A.K.4
Girouard, C.5
-
4
-
-
0028304010
-
MINE-ESHAP salvage therapy for recurrent and refractory lymphomas
-
Cabanillas, F.; Rodriguez, M.A. MINE-ESHAP salvage therapy for recurrent and refractory lymphomas. Semin. Hematol. 1994, 31 (2 Suppl. 3), 30.
-
(1994)
Semin. Hematol.
, vol.31
, Issue.2 SUPPL. 3
, pp. 30
-
-
Cabanillas, F.1
Rodriguez, M.A.2
-
5
-
-
0023818185
-
Effective salvage therapy for lymphoma with cis-platin in combination with high-dose Ara-C and dexamethasone (DHAP)
-
Velasquez, W.S.; Cabanillas, F.; Salvador, P.; McLaughlin, P.; Fridrik, M.; et al. Effective salvage therapy for lymphoma with cis-platin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988, 71 (1), 117-122.
-
(1988)
Blood
, vol.71
, Issue.1
, pp. 117-122
-
-
Velasquez, W.S.1
Cabanillas, F.2
Salvador, P.3
McLaughlin, P.4
Fridrik, M.5
-
6
-
-
0032761285
-
Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma
-
Moskowitz, C.H.; Bertino, J.R.; Glassman, J.R.; Hedrick, E.E.; Hunte, S.; et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 1999, 17 (12), 3776-3785.
-
(1999)
J. Clin. Oncol.
, vol.17
, Issue.12
, pp. 3776-3785
-
-
Moskowitz, C.H.1
Bertino, J.R.2
Glassman, J.R.3
Hedrick, E.E.4
Hunte, S.5
-
7
-
-
0029044083
-
Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP
-
Rodriguez, M.A.; Cabanillas, F.C.; Velasquez, W.; Hagemeister, F.B.; McLaughlin, P.; et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J. Clin. Oncol. 1995, 13 (7), 1734-1741.
-
(1995)
J. Clin. Oncol.
, vol.13
, Issue.7
, pp. 1734-1741
-
-
Rodriguez, M.A.1
Cabanillas, F.C.2
Velasquez, W.3
Hagemeister, F.B.4
McLaughlin, P.5
-
8
-
-
0019379808
-
Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine
-
Bergerat, J.P.; Drewinko, B.; Corry, P.; Barlogie, B.; Ho, D.H. Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1981, 41 (1), 25-30.
-
(1981)
Cancer Res.
, vol.41
, Issue.1
, pp. 25-30
-
-
Bergerat, J.P.1
Drewinko, B.2
Corry, P.3
Barlogie, B.4
Ho, D.H.5
-
9
-
-
0030886589
-
Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience
-
Rodriguez-Monge, E.J.; Cabanillas, F. Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience. Hematol. Oncol. Clin. North Am. 1997, 11 (5), 937-947.
-
(1997)
Hematol. Oncol. Clin. North Am.
, vol.11
, Issue.5
, pp. 937-947
-
-
Rodriguez-Monge, E.J.1
Cabanillas, F.2
-
10
-
-
2542643822
-
Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: A low probability of cure
-
Jabbour, E.; Chalhoub, B.; Suzan, F.; Aloulou, S.; Cainap, C.; et al. Outcome of elderly patients with aggressive Non-Hodgkin's lymphoma refractory to or relapsing after first-line CHOP or CHOP-like chemotherapy: a low probability of cure. Leuk. Lymphoma 2004, 45 (7), 1391-1394.
-
(2004)
Leuk. Lymphoma
, vol.45
, Issue.7
, pp. 1391-1394
-
-
Jabbour, E.1
Chalhoub, B.2
Suzan, F.3
Aloulou, S.4
Cainap, C.5
-
11
-
-
1842368507
-
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
-
Maloney, D.G.; Grillo-Lopez, A.J.; White, C.A.; Bodkin, D.; Schilder, R.J.; et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90 (6), 2188-2195.
-
(1997)
Blood
, vol.90
, Issue.6
, pp. 2188-2195
-
-
Maloney, D.G.1
Grillo-Lopez, A.J.2
White, C.A.3
Bodkin, D.4
Schilder, R.J.5
-
12
-
-
0033774970
-
Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines
-
Flieger, D.; Renoth, S.; Beier, I.; Sauerbruch, T.; Schmidt-Wolf, I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 2000, 204 (1), 55-63.
-
(2000)
Cell Immunol.
, vol.204
, Issue.1
, pp. 55-63
-
-
Flieger, D.1
Renoth, S.2
Beier, I.3
Sauerbruch, T.4
Schmidt-Wolf, I.5
-
13
-
-
0344766075
-
Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
-
Czuczman, M.S.; Grillo-Lopez, A.J.; White, C.A.; Saleh, M.; Gordon, L.; et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol. 1999, 17 (1), 268-276.
-
(1999)
J. Clin. Oncol.
, vol.17
, Issue.1
, pp. 268-276
-
-
Czuczman, M.S.1
Grillo-Lopez, A.J.2
White, C.A.3
Saleh, M.4
Gordon, L.5
-
14
-
-
0035863406
-
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
-
Vose, J.M.; Link, B.K.; Grossbard, M.L.; Czuczman, M.; Grillo-Lopez, A.; et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 2001, 19 (2), 389-397.
-
(2001)
J. Clin. Oncol.
, vol.19
, Issue.2
, pp. 389-397
-
-
Vose, J.M.1
Link, B.K.2
Grossbard, M.L.3
Czuczman, M.4
Grillo-Lopez, A.5
-
15
-
-
0037165261
-
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
-
Coiffier, B.; Lepage, E.; Briere, J.; Herbrecht, R.; Tilly, H.; et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002, 346 (4), 235-242.
-
(2002)
N. Engl. J. Med.
, vol.346
, Issue.4
, pp. 235-242
-
-
Coiffier, B.1
Lepage, E.2
Briere, J.3
Herbrecht, R.4
Tilly, H.5
-
16
-
-
0027444652
-
A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project
-
A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N. Engl. J. Med. 1993, 329 (14), 987-994.
-
(1993)
N. Engl. J. Med.
, vol.329
, Issue.14
, pp. 987-994
-
-
-
17
-
-
0042449063
-
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
-
NCI Sponsored International Working Group
-
Cheson, B.D.; Horning, S.J.; Coiffier, B.; Shipp, M.A.; Fisher, R.I.; et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 1999, 17 (4), 1244.
-
(1999)
J. Clin. Oncol.
, vol.17
, Issue.4
, pp. 1244
-
-
Cheson, B.D.1
Horning, S.J.2
Coiffier, B.3
Shipp, M.A.4
Fisher, R.I.5
-
18
-
-
0028261089
-
ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study
-
Velasquez, W.S.; McLaughlin, P.; Tucker, S.; Hagemeister, F.B.; Swan, F.; et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J. Clin. Oncol. 1994, 12 (6), 1169-1176.
-
(1994)
J. Clin. Oncol.
, vol.12
, Issue.6
, pp. 1169-1176
-
-
Velasquez, W.S.1
McLaughlin, P.2
Tucker, S.3
Hagemeister, F.B.4
Swan, F.5
-
19
-
-
0027182362
-
EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma
-
Wilson, W.H.; Bryant, G.; Bates, S.; Fojo, A.; Wittes, R.E.; et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J. Clin. Oncol. 1993, 11 (8), 1573-1582.
-
(1993)
J. Clin. Oncol.
, vol.11
, Issue.8
, pp. 1573-1582
-
-
Wilson, W.H.1
Bryant, G.2
Bates, S.3
Fojo, A.4
Wittes, R.E.5
-
20
-
-
1842829171
-
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
-
Kewalramani, T.; Zelenetz, A.D.; Nimer, S.D.; Portlock, C.; Straus, D.; et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004, 103 (10), 3684-3688.
-
(2004)
Blood
, vol.103
, Issue.10
, pp. 3684-3688
-
-
Kewalramani, T.1
Zelenetz, A.D.2
Nimer, S.D.3
Portlock, C.4
Straus, D.5
-
21
-
-
79960970775
-
High response rate and complete remission rate achieved by adding rituximab to Taxol and topotecan (TTR) with G-CSF support for the treatment of patients with relapsed/refractory aggressive B-cell lymphoma
-
Younes, A.; Mclauglin, P.; Hagemeister, F.B.; Pro, B.; Samaniego, F.; et al. High response rate and complete remission rate achieved by adding rituximab to Taxol and topotecan (TTR) with G-CSF support for the treatment of patients with relapsed/refractory aggressive B-cell lymphoma. Blood 2001, 98 (11), 345a.
-
(2001)
Blood
, vol.98
, Issue.11
-
-
Younes, A.1
Mclauglin, P.2
Hagemeister, F.B.3
Pro, B.4
Samaniego, F.5
-
22
-
-
0036178668
-
The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R
-
Wilson, W.H.; Gutierrez, M.; O'Connor, P.; Frankel, S.; Jaffe, E.; et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin. Oncol. 2002, 29 (1 Suppl. 2), 41-47.
-
(2002)
Semin. Oncol.
, vol.29
, Issue.1 SUPPL. 2
, pp. 41-47
-
-
Wilson, W.H.1
Gutierrez, M.2
O'Connor, P.3
Frankel, S.4
Jaffe, E.5
-
23
-
-
1842555344
-
Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: Results of a phase II study
-
Jermann, M.; Jost, L.M.; Taverna, C.; Jacky, E.; Honegger, H.P.; et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann. Oncol. 2004, 15 (3), 511-516.
-
(2004)
Ann. Oncol.
, vol.15
, Issue.3
, pp. 511-516
-
-
Jermann, M.1
Jost, L.M.2
Taverna, C.3
Jacky, E.4
Honegger, H.P.5
-
24
-
-
0032533888
-
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial. Parma Group
-
Blay, J.; Gomez, F.; Sebban, C.; Bachelot, T.; Biron, P.; et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998, 92 (10), 3562-3568.
-
(1998)
Blood
, vol.92
, Issue.10
, pp. 3562-3568
-
-
Blay, J.1
Gomez, F.2
Sebban, C.3
Bachelot, T.4
Biron, P.5
-
25
-
-
0026065050
-
Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation
-
Press, O.W.; Livingston, R.; Mortimer, J.; Collins, C.; Appelbaum, F. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J. Clin. Oncol. 1991, 9 (3), 423-431.
-
(1991)
J. Clin. Oncol.
, vol.9
, Issue.3
, pp. 423-431
-
-
Press, O.W.1
Livingston, R.2
Mortimer, J.3
Collins, C.4
Appelbaum, F.5
-
26
-
-
19944432350
-
A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma
-
Biagi, J.; Herbert, K.; Smith, C.; Abdi, E.; Leahy, M.; et al. A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leuk. Lymphoma 2005, 46 (2), 197-206.
-
(2005)
Leuk. Lymphoma
, vol.46
, Issue.2
, pp. 197-206
-
-
Biagi, J.1
Herbert, K.2
Smith, C.3
Abdi, E.4
Leahy, M.5
-
27
-
-
0031757275
-
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial
-
Guglielmi, C.; Gomez, F.; Philip, T.; Hagenbeek, A.; Martelli, M.; et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J. Clin. Oncol. 1998, 16 (10), 3264-3269.
-
(1998)
J. Clin. Oncol.
, vol.16
, Issue.10
, pp. 3264-3269
-
-
Guglielmi, C.1
Gomez, F.2
Philip, T.3
Hagenbeek, A.4
Martelli, M.5
-
28
-
-
0036256650
-
Treatment of relapsed aggressive lymphomas: Regimens with and without high-dose therapy and stem cell rescue
-
Hagemeister, F.B. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Cancer Chemother. Pharmacol. 2002, 49 (Suppl. 1), S13-20.
-
(2002)
Cancer Chemother. Pharmacol.
, vol.49
, Issue.SUPPL. 1
-
-
Hagemeister, F.B.1
-
29
-
-
0031045771
-
Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas
-
Caballero, M.D.; Amigo, M.L.; Hernandez, J.M.; Vazquez, L.; del Canizo, C.; et al. Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas. Ann. Hematol. 1997, 74 (2), 79-82.
-
(1997)
Ann. Hematol.
, vol.74
, Issue.2
, pp. 79-82
-
-
Caballero, M.D.1
Amigo, M.L.2
Hernandez, J.M.3
Vazquez, L.4
Del Canizo, C.5
-
30
-
-
0033955394
-
Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure?
-
Josting, A.; Reiser, M.; Rueffer, U.; Salzberger, B.; Diehl, V.; Engert, A. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J. Clin. Oncol. 2000, 18 (2), 332-339.
-
(2000)
J. Clin. Oncol.
, vol.18
, Issue.2
, pp. 332-339
-
-
Josting, A.1
Reiser, M.2
Rueffer, U.3
Salzberger, B.4
Diehl, V.5
Engert, A.6
-
31
-
-
4644226626
-
Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma
-
Leo, E.; Scheuer, L.; Schmidt-Wolf, I.G.; Kerowgan, M.; Schmitt, C.; et al. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. Eur. J. Haematol. 2004, 73 (4), 251-257.
-
(2004)
Eur. J. Haematol.
, vol.73
, Issue.4
, pp. 251-257
-
-
Leo, E.1
Scheuer, L.2
Schmidt-Wolf, I.G.3
Kerowgan, M.4
Schmitt, C.5
-
32
-
-
16544369964
-
Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma
-
Hoerr, A.L.; Gao, F.; Hidalgo, J.; Tiwari, D.; Blum, K.A.; et al. Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphoma. J. Clin. Oncol. 2004, 22 (22), 4561-4566.
-
(2004)
J. Clin. Oncol.
, vol.22
, Issue.22
, pp. 4561-4566
-
-
Hoerr, A.L.1
Gao, F.2
Hidalgo, J.3
Tiwari, D.4
Blum, K.A.5
-
33
-
-
0025896583
-
Parma International protocol: Pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation
-
Philip, T.; Chauvin, F.; Armitage, J.; Bron, D.; Hagenbeek, A.; et al. Parma International protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991, 77 (7), 1587-1592.
-
(1991)
Blood
, vol.77
, Issue.7
, pp. 1587-1592
-
-
Philip, T.1
Chauvin, F.2
Armitage, J.3
Bron, D.4
Hagenbeek, A.5
-
34
-
-
0038511330
-
Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma
-
Vose, J.; Sneller, V. Outpatient regimen rituximab plus ifosfamide, carboplatin and etoposide (R-ICE) for relapsed non-Hodgkin's lymphoma. Ann. Oncol. 2003, 14 (Suppl. 1), i17-20.
-
(2003)
Ann. Oncol.
, vol.14
, Issue.SUPPL. 1
-
-
Vose, J.1
Sneller, V.2
|